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Introduction
Acid-related upper gastrointestinal disorders are common in the developed world [1] . Consequently, proton pump inhibitors (PPIs) to treat these disorders are among the most widely prescribed medications worldwide [1, 2] . PPIs are indicated for several acid-related upper gastrointestinal disorders, including gastro-oesophageal disease (GERD), dyspepsia, peptic ulcer disease and as prophylaxis for non-steroidal anti-inflammatory drugs-associated upper gastrointestinal complications [3] . Due to their effectiveness and perceived short-and long-term safety, PPIs account for 95% of acid suppressing medication prescriptions [1] . In Australia, PPI prescribing tripled from 45 in 2001 to 130 defined daily dose (DDD)/1000 concession beneficiaries/day in 2005 [4] . With 6.9 million prescriptions in 2014, PPIs are the third most prescribed drug group by volume and the fourth highest cost prescribed drug group in Australia [5] . The total number of dispensed prescriptions for PPIs increased by 28% from approximately 74 million prescriptions in 2002 to 95 million prescriptions in 2009 [6] .
More recently, a growing concern is the safety of PPIs; several adverse effects of long term PPI use have been reported, including decreased bone quality [3, 7] . Warnings about PPIs and potentially increased fracture risk have been issued in Australia and in the US [8, 9] . In 2011, a meta-analysis by Kwok et al. [7] (observing 4 prospective cohort studies and 8 retrospective studies, of which 6 case-control studies) confirmed an increased risk of fracture following PPI use, presumably due to the development of osteoporosis. In 2014, a prospective cohort study by Moberg et al. [10] found that postmenopausal women using PPI's were having a more than double increased fracture risk (odds ratio=2.53, confidence intervals (CI)=1. 28-4.99) . If a causal relationship exists between PPIs and fractures, the predisposing factors for fractures are expected to be affected. However, studies examining associations between PPI use and bone mineral density (BMD) found none or little evidence for an association between PPI use and the development of osteoporosis [11] [12] [13] [14] [15] . In contrast, a study by Maggio et al. [16] found that PPI use was significantly associated with decreased trabecular BMD, possibly an early marker of osteoporosis. One study found that PPI-users were more likely to subsequently be prescribed osteoporosis medication than non-users and that increased duration of therapy was associated with higher risks of osteoporosis medication prescription [1] . Three studies examining the effect of PPI use on calcium uptake used the dual isotope test (golden standard for intestinal calcium absorption) and these showed no evidence for decreased calcium absorption among PPI users [17] [18] [19] .
Overall, it remains unclear whether PPIs indeed have a significant effect on bone metabolism [7] .
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Previous studies typically compared all PPI users with non-users, while the effect may depend on dose or type of PPI. Investigation of dose and type of PPI use not only gives more insight into the reported adverse effects on bone health, but also may have important implications for prescribing. The study objective was to examine the effect of dose and type of PPI use on subsequent use of osteoporosis medication and fractures in older Australian women from 2003 to 2011. It was hypothesized that PPI use negatively influences bone health resulting in both increased osteoporosis medication prescription and fracture incidence.
Methods
Study sample
Data were from the Australian Longitudinal Study on Women's Health (ALSWH), a prospective study of demographic, social, physical, psychological, and behavioural variables and their effect on women's health, wellbeing and health service use [20] . In 1996, participants were selected from the database of the Health Insurance
Commission that ran the national health insurance scheme (Medicare For the current study, data were used from the older women (born 1921-1926) . Prescriptions for PPI and osteoporosis medication were publically subsidized and neither group of medications is available for purchase overthe-counter. In 1996, 12432 older women completed the initial survey (response rate 37-40%) [20] . Since then, five follow-up surveys have been completed at 3-year intervals. As linked pharmaceutical data were available from 2002 onward, the 2002 survey (ages 76-81 years, n=8646) was used as baseline. Data were excluded from women who:
(1) completed a short version of the survey; (2) did not consent to data linkage; [23] . Three categories were created: non-user, <400 DDD, ≥400 DDD.
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Subsequent use of osteoporosis medication
Users of osteoporosis medication were defined as having ≥1 prescriptions recorded for alendronate, zoledronic acid, risedronate, disodium etidronate, strontium ranelate, denosumab, teriparatide, raloxifene, ergocalciferol, calcitriol, colecalciferol or calcium supplements specific for osteoporosis between January 2003 and December 2011 (inclusive). Indications for subsidy have been published previously [24] . Ergocalciferol, calcitriol, colecalciferol and calcium supplements were dispensed with government subsidy only after diagnosis with osteoporosis after minimal trauma fracture.
Subsequent fractures
Admission data and International Classification of Diseases-10 (ICD-10) codes for any fractures recorded between January 2003 and June 2011 (inclusive) in the hospital administrative records were used as data sources to identify participants with fractures.
Other variables
The variables obtained by self-report in the 2002 ALSWH survey and included in the analysis and were alcohol consumption, smoking, level of education, age, physical functioning, physical activity, area of residence, body mass index (BMI), number of general practitioner consultations, and chronic conditions. BMI (kg/m 2 ) was calculated using self-reported height and weight. Alcohol status was categorized as ‗‗low-risk drinker'', ‗‗non-drinker'', ‗‗rarely drinks'', ‗‗risky drinker'', ‗‗high-risk drinker'' [25] . Smoking status (1999 survey) was defined as nonsmoker or smoker based on the question ‗‗How often do you currently smoke cigarettes or any tobacco products?''
Level of education (1996 survey) was assessed as the highest qualification completed, ranging from -no formal qualification‖ to -university degree or higher‖. Physical functioning was based on the physical functioning subscale (0-100) of the SF-36, which measures health-related quality of life [26] . Self-rated health was assessed with the ; moderate (600-<1200); or high (1200+) MET.min/week [27] . Area of residence was categorized as urban, rural, and remote. Number of chronic conditions was assessed by summing the self-report of hypertension, arthritis, heart attack, angina pectoris, other heart disorder, diabetes, asthma, bronchitis, stroke, cancer (except skin cancer), depression, and dementia (range 0-12).
To control for potential modifying or confounding effects of other medications based on the literature [28] [29] [30] , further data were obtained from the linked PBS database. The medications considered were thyroid hormones, 
Statistical analysis
Sample characteristics were compared between PPI-users and non-users with the t-test (age, BMI), the MannWhitney U test (chronic conditions, physical functioning) and the chi-squared test (all categorical variables). A pvalue of <0.05 was considered statistically significant. All analyses were conducted with STATA version 11.2 (StataCorp LP. College Station, TX).
The association between PPI use and subsequent use of osteoporosis medication and fractures were examined using competing risk regression models, and reported as sub-hazard ratios (SHRs) with 95% CI. The SHR is the ratio of hazards associated with the cumulative incidence function in the presence and absence of the exposure variable. PPI was set up as a time-dependent covariate to prevent both immortal selection bias (which occurs when follow-up starts with first PPI exposure; i.e. time when use of osteoporosis medication, fractures or death cannot occur is omitted for PPI-users) and immortal misclassification bias (which occurs when participants who become PPI-users after the start of study are classified as PPI-users during the whole follow-up) [31, 32] . Robust standard errors were used to account for counting PPI-users twice.
The analyses were conducted without adjustment and after adjustment for age and area of residence, plus any of the survey and other medication variables that were statistically significantly associated with PPI use and/or use of
osteoporosis medication or fractures. Potential interaction with any of the other medications was tested by adding interaction terms (PPI use x medication). Subsequently, the model was stratified for medication use if a statistically significant interaction was identified.
To determine a potential effect of dosage and duration of treatment on subsequent use of osteoporosis medication or fractures, analyses were repeated for PPI categorized according to DDD. In this model, DDD was the timedependent variable with ≥400 DDD users put in the model first as a non-user, then as a <400 DDD user from the day of first PPI claim and subsequently as a ≥400 DDD user from the day of first claim adding up to >400 DDD. To examine the effect of type of PPI, the model fitting was repeated for each type of PPI separately compared with PPI non-users.
Results
During an average follow-up of 6.6 years for use of osteoporosis medication, 2328 of the 4432 participants started PPI therapy. During an average follow-up of 7.6 years for fractures, 1396 of the 2734 participants with available linked hospital data started PPI therapy (Figure 1 ). PPI-users were more likely than PPI non-users to score lower on Table   2 ). The cumulative incidence function comparing use of osteoporosis medication between PPI-users and non-users is shown in Figure 2 . No statistically significant interactions were found for PPI use with any other medications; stratification for other medication use was therefore not required.
Hospital linked data were available for 62% of this cohort of ALSWH participants (2734/4432). These data showed a significant higher risk of fracture after PPI use (SHR=1.34, CI=1.12-1.60) ( Table 3 ). This association remained statistically significant after adjustment.
Analysis with PPI categorized according to total dosage (DDD) showed some evidence for a dose-response effect (Tables 2 and 3 (Table 3) .
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Figure 2 Cumulative incidence of osteoporosis medication use in PPI users and non-users (Single-column fitting image)
Abbreviations: PPI, proton pump inhibitor. 
Descriptive caption: Cumulative incidence function of osteoporosis medication use for PPI non-users and PPI users during study follow-up (2003-2012).
Discussion
The results from this prospective cohort study support the hypothesis that PPI use is associated with an increased risk of subsequent use of osteoporosis medication and fractures in older women. These associations were strongest in the users of esomeprazole and rabeprazole. There was some evidence for a dose-response association.
Osteoporosis medications are subsidized on PBS for women with a BMD T-score of <-3 or a minimal trauma fracture, which means that this outcome includes women with a low BMD, women with a fracture and women with both low BMD and a fracture. The PBS administrative database does not distinguish between these diagnoses. In our subsample with hospital data, 32.5% had both osteoporosis medication and a fracture, which suggests that use of osteoporosis medication in this population mainly reflects the low BMD diagnosis. The results for both outcomes pointed in the same direction, which strengthens the evidence for a negative association between PPI use and bone health. Most other studies examined associations between PPI use and only one of these or other indicators of bone health (e.g. BMD). Our findings are consistent with the only other study [1] that used osteoporosis medication as an indicator of bone health. The results of studies with other outcomes are inconsistent. A meta-analysis by Kwok et al. [7] confirmed an increased fracture risk after the use of PPIs . In contrast, only one [13] of five prospective studies [11] [12] [13] [14] [15] found a significant negative association between PPI use and BMD at the hip, but not at other sites.
Additionally a negative association was found for PPI use and trabecular BMD, but not for cortical BMD by Maggio et al. [16] . Except for the prospective cross-sectional study by Targownik et al. [11] , the studies investigating PPI use and BMD were prospective cohort studies (Canadian Multicentre Osteoporosis Study (CaMos) [12] , Women's Health Initiative (WHI) Observational Study and Clinical Trials [13] , Osteoporotic Fractures in Men Study (MrOS) and Study of Osteoporotic Fractures (SOF) [14] , and Study of Women's Health Across the Nation (SWAN) [15] ).
Several explanations are possible for the discrepancy in findings with fractures and BMD in previously published studies. First, in a study by Wainwright et al. [33] half of the older women with fractures did not have a BMD in the osteoporotic range. Therefore measuring BMD may not be an accurate reflection of fracture risk. Furthermore, a recent randomized controlled trial by Itoh et al. [34] showed that bisphosphonate (an osteoporosis medicine) in combination with PPI use is more effective regarding physical fitness and BMD than solely bisphosphonate use.
These results could reflect a more protective value of osteoporosis medication regarding fracture risk in PPI users due to improved physical fitness rather than a ‗healthy' BMD. Second, it could be that the mechanism explaining the relationship between PPI use and fracture risk is not by decreasing BMD, but by other aspects of bone microarchitecture which are not measured with DEXA scans [35] . Third, it may be that PPI use affects the fall risk and subsequently the fracture risk, without having a direct effect on bone quality [36] . Fourth, the inconsistent findings may be explained by differences between studies in study design and sample characteristics. Variations in inclusion and exclusion criteria between studies may have influenced the prevalence of both PPI and the outcome. Typically, studies have excluded participants with a fracture or osteoporosis medication before initiation of PPIs, rather than included them as PPI non-users, which may have led to immortal time bias [32] . Immortal time bias appears in pharmacoepidemiological cohort studies when the study design requires the treated group to survive until the treatment begins and results in overestimation of the effect sizes [31] . Fifth, variation in the types of PPI studied may also explain differences between studies, as we found that some but not all PPIs were associated with increased OAM use and fracture risk. More prospective studies examining the associations between types of PPIs and a combination of bone health measures are needed to understand mechanisms behind the relationship between PPI use and fractures. Including PPI use as a time-varying covariate is essential to avoid immortal time bias.
The current findings provide some evidence of a dose-response relationship between PPI use and subsequent adverse bone health indicators. Although there was a trend of increased effect with increased total dose, this was not statistically significant (i.e. the confidence intervals overlapped). Our measure of cumulative dose included both dose and duration component. In a meta-analysis by Kwok et al. [7] , increased duration of PPI use was associated with higher risk ratios for fractures. Two more recent studies showed evidence for an increased fracture risk after long-term PPI use in older adults [10, 37] . In contrast, a study by Soriano et al. [38] showed a higher hip fracture risk after short-term PPI use, but not after long-term PPI use. It could be that in this study, PPI users who experience adverse effects on the short term switched to a different type of PPI or an H2 blocking agent resulting in a null effect on the long-term. This is supported by our finding that risks for fracture and use of osteoporosis medication were particularly high among those who used multiple types of PPIs. Given these inconclusive findings, future research should differentiate between dose and duration to better understand their potential influences on bone health.
When the analyses in the present study were repeated for each type of PPI separately, increased use of osteoporosis medication and risk of fractures were found for users of rabeprazole. Additionally an increased risk for subsequent use of osteoporosis medication was found for users of esomeprazole. Multiple PPI users also showed increased use of osteoporosis medication and subsequent fracture risk. So far, no other studies have analyzed specific effects of PPI type on bone health. The higher risk of osteoporosis medication and fractures after rabeprazole than other PPIs, could be supported by the results of a study by Ishizaki et al. [28] , in which the biotransformation of rabeprazole in the liver differed from other PPIs. Esomeprazole is a single enantiomer of omeprazole and logic would dictate that esomeprazole should be given at half the dose of omeprazole for equivalent efficacy. However, this is not the case in clinical practice and in fact esomeprazole is often given at twice the dose (presumably four times as potent) as omeprazole, and it could be that the association of osteoporosis medication and fractures with esomeprazole is just because of the higher dose of active PPI being given. Furthermore, findings from a study by Kirchheiner et al. [39] showed higher clinical potency for rabeprazole and esomeprazole, which is consistent with the current findings of increased subsequent prescription of osteoporosis medication after rabeprazole and esomeprazole use. Additionally, a prospective study by Bahtiri et al. [40] found that only esomeprazole use out of 4 studied PPI types, was practice. This is particularly relevant as esomeprazole has become the most widely prescribed PPI in Australia since first subsidy in 2002 and was prescribed to 12% of the total cohort of elderly women in this study (and over a fifth of the PPI users) [5] .
The strengths of this current study include the large sample size (n=4432), the prospective cohort design, adjustment for main confounders and an advanced analytical model. We have unique linked datasets, including many factors in addition to the medication dispensed, for each woman. The model took into account competing risks (death) and avoided immortal time bias (i.e. selection and/or misclassification bias) [31] , by analysing PPI use as a timedependent covariate.
Several limitations should be taken into account when interpreting the current results. Although many confounders were included, residual confounding may exist. Other studies have suggested some potential confounding variables that were not measured in the current study, including vitamin B12 deficiency, community acquired pneumonia, clostridium difficile, Helicobacter pylori [3, 41] and celiac disease [42] . The large population based case-control study by Lam et al. [41] on PPI use and vitamin B12 deficiency, showed a significant association between previous and current PPI use and the existence of a vitamin B12 deficiency. In addition a recent review by Bailey et al. [43] found that vitamin B12 deficiency is associated with an increased fracture risk, whereas no significant effect of a vitamin B12 deficiency on BMD was found. Vitamin B12 deficiency could be a mediator rather than a confounder in the current study. Vitamin B12 deficiency caused by PPI use, could perhaps be considered as a potential mechanism leading to an increased fracture risk in PPI users, but further data would be required to explore this hypothesis. Higher dose corticosteroid use only was considered, not lower dose which might possibly be a residual confounder [35] . To measure co-morbidity, insufficient information was available to use validated indices such as those developed by Charlson or Elixhauser and we were limited to using number of chronic conditions reported from a selected list. The accuracy of self-report of chronic conditions varies across conditions, but is generally accepted for use in epidemiological studies where clinical examination of each of the conditions is not feasible [44, 45] . The proportion of participants with 12+ GP consultations was greater in PPI users than non-users ( Table 1 ).
The higher rate of health services use among PPI users may suggest that these women were more likely to be diagnosed with or treated for osteoporosis based on exposure to physicians alone. However, the number of GP consultations did not differ between participants with and without use of osteoporosis medication and additional adjustment for GP consultations did not alter the results for use of osteoporosis medication (SHR=1.28, CI=1.13-1.45, p<0.001 for PPI users compared with non-users). No information was available about compliance with PPI use; therefore, the study is based on dispensed PPIs rather than actual intake. It is known that osteoporosis is an underdiagnosed as well as undertreated condition [46] . Although treatment with osteoporosis medication may not be a good measure of osteoporosis given the compliance issues, it is likely that when first diagnosed with osteoporosis most patients will be dispensed an osteoporosis medication at least once. As our outcome was based on time to the first prescription, it is likely that we included the majority patients who had an osteoporosis diagnosis. Furthermore, a previous study in this sample showed substantial agreement between self-reported medication use and osteoporosis treatment [24] . The fractures outcome was based on hospital admission data, which means that only those fractures were included that led to hospital admission. No information is available of fractures that did not require hospitalization. However, as these community-dwelling women were quite elderly, it is likely that the majority of fractures would have resulted in hospital admission. Finally, comparing sample characteristics between participants who were included with those who were excluded in the data analyses, suggested that included participants were more educated, healthier and had better lifestyles and levels of functioning. Hence, the current sample represents a group of relatively healthy older women (77-82 at the start of follow-up) and the study results may not be generalizable to other age groups and to men.
In March 2013, the American College of Gastroenterology published new guidelines for the treatment of GERD, which reflect the ongoing doubts and concerns about potential adverse effects of PPI treatment. In these guidelines, the potential adverse effects of PPI use on bone are mentioned, but without implications for the prescription of PPIs [47] . However, the current results add to the evidence that PPI use is associated with decreased bone quality. Given the widespread use of PPIs and the high morbidity and mortality associated with osteoporotic fractures, an increased risk of fractures and osteoporosis attributable to PPI use could lead to a notable effect in the population health and health-related costs. Moreover a recent study by Huang et al. [48] showed that there was no effect of osteoporosis treatment with calcitriol in people using esomoprazole. These findings highlight the need for a more careful approach to PPI prescription, as treating resulting osteoporosis may not be easy. As PPI treatment is often continued without verification or repeated confirmation of indication and/or lowest dose prescription, treatment on demand and step-down therapy should be considered more often [3, 49] .
Conclusion
PPI use was associated with significantly increased subsequent use of osteoporosis medication and fractures. These associations existed for use of rabeprazole and esomeprazole. This is important as esomeprazole was the most commonly prescribed PPI (22.9% of PPI users). The current results support the hypothesis that PPI use negatively affects bone health. These findings foreshadow the need for a more cautious approach than the current widespread prescribing of PPIs. Different PPIs may have differing effects on changing bone quality.
